CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.

Although it is well known that CD8(+) cytotoxic T lymphocytes (CTLs) play an important role in the suppression of cancer cell growth, the significance of CD4(+) CTLs in resistance to cancer is obscure. In an attempt to elucidate the role of CD4(+) CTLs in immunosurveillance of chronic myelogenous leukemia (CML), we examined the immunologic functions of bcr-abl b3a2 fusion peptide-specific CD4(+) CTL clones. Seven CD4(+) T-cell clones that responded to stimulation with b3a2 peptide, but not with b2a2 peptide or physiological counterparts bcr b3b4 and abl 1A-a2 peptides, were established from two healthy individuals. Restriction elements of these clones were HLA-DRB1*0901. These CD4(+) T-cell clones exhibited b3a2 peptide-specific and HLA-DRB1*0901-restricted cytotoxicity and produced interleukin-3 (IL-3), IL-4, IL-10, interferon-gamma, tumor necrosis factor-alpha, and granulocyte-macrophage colony-stimulating factor in response to bcr-abl peptide stimulation, indicating they were Th0 clones. The numbers of HLA-DRB1*0901-positive b3a2, but not those of b2a2-positive or HLA-DRB1*0901-negative CML cell colonies increased when CML cells were cultured with b3a2-specific CD4(+) CTL clones. These data suggest that bcr-abl-specific CD4(+) CTLs recognize CML cells in an antigen-specific and HLA-DR-restricted manner, and that they do not inhibit, but in fact augment, CML cell growth.

[1]  A. Barrett,et al.  Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. , 1997, Blood.

[2]  J. Guillet,et al.  Peptides derived from the whole sequence of BCR‐ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes , 1997, European journal of immunology.

[3]  J. McKenzie,et al.  HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates. , 1997, Blood.

[4]  J. Ting,et al.  Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Zinkernagel,et al.  Functional in vivo MHC class II loading by endogenously synthesized glycoprotein during viral infection. , 1997, Journal of immunology.

[6]  N. Young,et al.  Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. , 1997, Blood.

[7]  C. Melief,et al.  Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. , 1996, Blood.

[8]  J. Melo,et al.  The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. , 1996, Blood.

[9]  G. Pawelec,et al.  BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. , 1996, Blood.

[10]  A. Barrett,et al.  Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen , 1996, British journal of haematology.

[11]  A. Sette,et al.  Specific human cellular immunity to bcr-abl oncogene-derived peptides. , 1996, Blood.

[12]  D. Accapezzato,et al.  Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes , 1996 .

[13]  S. Matsushita,et al.  Identification of HLA-DR9 (DRB1*0901)-binding peptide motifs using a phage fUSE5 random peptide library. , 1996, Human immunology.

[14]  H. Kantarjian,et al.  CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. , 1995, Blood.

[15]  C. Melief,et al.  Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. , 1995, Leukemia.

[16]  J. Sidney,et al.  Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. , 1995, Blood.

[17]  A. Houghton,et al.  Reactivity of autologous CD4+ T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. , 1995, Journal of immunology.

[18]  S. Yonehara,et al.  Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Ju,et al.  Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Erb,et al.  Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. , 1994, Journal of immunology.

[21]  S. Fujita,et al.  Specificity analysis of human CD4+ T-cell clones directed against human herpesvirus 6 (HHV-6), HHV-7, and human cytomegalovirus , 1993, Journal of virology.

[22]  S. Carding,et al.  A polymerase chain reaction assay for the detection and quantitation of cytokine gene expression in small numbers of cells. , 1992, Journal of immunological methods.

[23]  Wei Chen,et al.  T-cell immunity to the joining region of p210BCR-ABL protein. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[24]  S. Weiss,et al.  MHC class II—Restricted presentation of intracellular antigen , 1991, Cell.

[25]  T. Horiuchi,et al.  Functional heterogeneity among herpes simplex virus-specific human CD4+ T cells. , 1991, Journal of immunology.

[26]  Eric O Long,et al.  An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytoplasmic antigens to class II-restricted T cells , 1990, The Journal of experimental medicine.

[27]  R. Klausner,et al.  Class II MHC molecules can use the endogenous pathway of antigen presentation , 1990, Nature.

[28]  M. Yasukawa,et al.  Differential in vitro activation of CD4+CD8- and CD8+CD4- herpes simplex virus-specific human cytotoxic T cells. , 1989, Journal of immunology.

[29]  P. Greenberg,et al.  Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. , 1986, Journal of immunology.

[30]  E. Canaani,et al.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia , 1985, Nature.

[31]  Kees Stam,et al.  Structural organization of the bcr gene and its role in the Ph′ translocation , 1985, Nature.

[32]  H. McFarland,et al.  Measles virus-specific T4+ human cytotoxic T cell clones are restricted by class II HLA antigens. , 1984, Journal of immunology.

[33]  M. Yasukawa,et al.  Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. I. Lysis restricted by HLA class II MB and DR antigens. , 1984, Journal of immunology.

[34]  J. Strominger,et al.  Long-term human cytolytic T-cell lines allospecific for HLA-DR6 antigen are OKT4+. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Zinkernagel,et al.  Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. , 1996, Annual review of immunology.

[36]  R. Lechler,et al.  Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: studies in antigen-processing defective cell lines. , 1994, Leukemia.

[37]  W. Chen.  T cell immunity to the joining region of p210^ protein. , 1992 .

[38]  C. Janeway,et al.  Cloned helper T cells can kill B lymphoma cells in the presence of specific antigen: Ia restriction and cognate vs. noncognate interactions in cytolysis , 1984, European journal of immunology.